448P Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice

Mikhail Fedyanin, H. Elsnukaeva,I. A. Demidova,Daniil Stroyakovskiy,Yuri A. Shelygin, A. S. Tsukanov,Maria V Panina,Fedor Moiseenko, E. Karpenko,Larisa Bolotina,Anna V. Kudryavtseva,Maksim L. Filipenko, I. Oskorbin,Liubov Yu Vladimirova,Natalya N. Timoshkina, O. Kit,Anna Stroganova,Svetlana Dranko,Alexey Tryakin, S. A. Tjulandin

ANNALS OF ONCOLOGY（2021）

引用 0|浏览4

暂无评分

摘要

Combination of BRAF inhibitors and anti-EGFR antibodies is a standard of 2nd and subsequent line of treatment in pts with mBRAF mCRC. We performed analysis of prospective multicentric database of pts with mBRAF metastatic CRC to evaluate the efficacy of such approach in the real clinical practice.

查看译文

关键词

metastatic colorectal carcinoma,braf inhibitors,mbraf,anti-egfr

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要